New Article by WTD Chairman Published in ‘The Lancet Haematology’

March 24, 2016

Extended Duration of Anticoagulation with Edoxaban in Patients with Venous Thromboembolism: A Post-Hoc Analysis of the Hokusai-VTE Study

By Gary Raskob, Walter Ageno, Alexander T Cohen, Marjolein P A Brekelmans, Michael A Grosso, Annelise Segers, Guy Meyer, Peter Verhamme, Philip S Wells, Min Lin, Shannon M Winters, Jeffrey I Weitz, Harry R Bueller 

Background

There are few data on the relative efficacy and safety of direct oral anticoagulants, such as edoxaban, compared with vitamin K antagonists during extended therapy for venous thromboembolism. This analysis evaluates the risk–benefit of extended treatment for up to 12 months with edoxaban compared with warfarin among patients enrolled in the Hokusai-VTE study who continued therapy beyond 3 months.

CONTINUE READING…

*Article originally published in The Lancet Haematology

Related Campaign News

  • In this series, World Thrombosis Day (WTD) shares interviews with members [...]

  • World Thrombosis Day (WTD) is a global campaign that aims to [...]

  • In this new series, World Thrombosis Day (WTD) shares interviews with [...]